Breast Cancer

Although 5 years of neoadjuvant endocrine therapy improves disease-free survival in patients with early-stage breast cancer, the optimal duration of adjuvant therapy beyond 5 years has yet to be established. Results of a new study, suggesting that longer is not necessarily better, provide further insight on this topic.
An evaluation of more than 200 patients with breast cancer showed a near doubling of the risk for contralateral disease with dense breast tissue. This information may help clinicians counsel patients on their personal risk and options for treatment and surveillance.
Adding pertuzumab to standard therapy in women with HER2-positive/HR-positive locally advanced or metastatic breast cancer increased PFS, with no new safety signals identified.
No significant difference was found in survival between BRCA gene carriers and noncarriers among young patients with breast cancer. In addition, a consistent survival advantage was found in favor of BRCA carriers presenting with triple-negative breast cancer.
New data confirm the heterogeneity of HER2-positive breast cancer and may identify a subgroup of patients who benefit from dual HER2 blockade without the use of chemotherapy.
The largest study to date comparing outcomes of radiation therapy and postmastectomy breast reconstruction found higher rates of complication and failure in women who received radiation therapy and had implant reconstruction versus autologous reconstruction.
Endocrine therapy is known to reduce breast cancer risk by 30% when used as primary prevention in women at risk for the disease, and the reduction lasts for at least 20 years.
Breast cancer rates are increasing worldwide, paralleling increases in type 2 diabetes, obesity, and metabolic syndrome (MetS).
Breast density, which can affect the visualization of mammography, is one of the strongest and most consistent risk factors for breast cancer.
Occupational factors such as shift work disrupt circadian rhythm and can increase breast cancer risk, and the International Agency for Research on Cancer has classified shift work as a possible carcinogen.
Page 1 of 12
Results 1 - 10 of 116